Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum by unknown
IMMUNOGLOBULIN G ANTIBODIES DIRECTED AGAINST
PROTEIN III BLOCK KILLING OF SERUM-RESISTANT
NEISSERIA GONORRHOEAE BY IMMUNE SERUM
BY PETER A. RICE, HAROLD E. VAYO, MILTON R. TAM, AND
MILAN S. BLAKE
From The Maxwell Finland Laboratoryfor Infectious Diseases, Boston City Hospital, Boston
University School ofMedicine, Boston, Massachusetts 02118; Genetic Systems,
Seattle, Washington 98121; and the Laboratory ofBacteriology and Immunology, The
Rockefeller University, New York 10021
Resistance to killing by normal human serum (NHS)' and complement is
exhibited by most strains of Neisseria gonorrhoeae that cause disseminated gono-
coccal infection (DGI) (1). This phenotypic property of DGI strains is in contrast
to that often observed in strains that cause locally invasive disease, e.g., pelvic
inflammatory disease (PID), which frequently are highly sensitive to NHS (2).
This feature may identify strains that are capable ofpromoting local inflamma-
tion (2). On the other hand, DGI strains usually cause no local symptoms (3).
This may enable DGI strains to evade local defenses (4), penetrate local barriers,
and invade the bloodstream. Serum-resistant organisms are also disproportion-
ately represented in asymptomatic men (5) who do not develop disseminated
infection.
The mechanisms ofserum resistance and sensitivity are directly related to the
efficiency of insertion of the membrane attack complex of complement (C5b-9)
(6). Activation and deposition of individual complement components onto the
surface of organisms either directly or via antibody are not sufficient, however,
to ensure complete insertion of the membrane attack complex (MAC) (7, 8).
Natural antibodies of the IgG class may subvert adequate insertion ofthe MAC.
These have been described in human sera, and are termed blocking antibodies
(7-9). These antibodies interfere with the efficient insertion of the MAC by as
yet unknown mechanism(s); however, binding of these antibodies to particular
antigenic targets on the surface of the gonococcus may divert the necessary
localization of complement (C) away from bactericidal sites (7). Recent studies
using murine monoclonal antibodies (mAb) have shown that antibody specific
for a gonococcal surface protein, protein III, is able to block killing ofgonococci
by bactericidal antibody directed against a separate epitope (10). Protein III
appears to be not only present in all strains of gonococci (11, 12), but biochem-
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ically and immunochemically identical (12, 13) . In earlier studies, we have shown
that IgG prepared from NHS with blocking activity contains antibody specificity
for outer membrane proteins (9, 14). The studies reported here investigate the
unique antigenic specificity of human blocking antibody and demonstrate the
blocking action of purified IgG antibodies directed against gonococcal outer
membrane protein III (PIII).
Strain
Materials and Methods
A single serum-resistant strain of N. gonorrhoeae isolated from the joint of a patient
with disseminated gonococcal infection (DGI-1) was used in these studies. This strain
resisted killing by 10 fresh NHS at serum concentrations of 66.7% and has a protein I
(PI) of M, 36,200. It is in the IB-3 serovar group (15), kindly serotyped by Dr. Joan
Knapp, Centers for Disease Control, Atlanta, GA, and auxotyped as Pro (16).
Serums
Convalescent serum from the patient (DGI-1 immune serum), which expressed bacte-
ricidal activity against the infecting strain, was obtained 22 d after infection and used as
the source of bactericidal antibody. Bactericidal antibody in this serum is directed against
lipooligosaccharide (LOS) (17, 18) similar to other serums obtained from DGI patients in
convalescence that sometimes express bactericidal activity against strains resistant to killing
by NHS (1, 3). Blocking activity was identified using a previously described assay (9) in 4
U of citrated plasma (converted to serum by the addition ofCaC12 to a final concentration
of 0.15 M). Serum with blocking activity was recovered from this material and pooled.
We also identified a second DGI convalescent serum (DGI-2 serum) that exhibited <50%
killing against the DGI-1 test strain when used in the bactericidal assay at a concentration
of 66.7% . Specific antibody was depleted from this serum to attempt the removal of
blocking activity.
Growth of Organisms
Transparent (Op-), nonpiliated (P-) phenotypes of DGI-1 gonococci were grown in
mass culture. Preparation of outer membranes, isolated proteins, and LOS was accom-
plished using organisms that were grown on a solid clear media (19) for 16 h at 37° C in
candle extinction jars or on liquid culture as previously described (20).
Preparation ofAntigens
Preparation of outer membranes was performed according to methods, which we have
described previously (17), that yield membranesjudged pure by their uniform density, p°
= 1 .27 g/cms and absence of D-lactate dehydrogenase activity. Protein I was purified as
described (21) and the purification of protein III was accomplished by methods described
by Lytton and Blake (see preceding article [22]). These isolated proteins were assessed for
purity by SDS-PAGE (23, 24) analysis and staining with silver nitrate (25, 26) and also for
antigenicity in Western blotting (27) experiments that used specific murine mAb. mAb
2E6 exhibits specificity for protein III (13), and 3C8 recognizes a determinant present on
protein I of the IB-3 serovar (15). LOS was prepared from whole organisms using a
modification (28) of hot phenol/water extraction (29). This preparation and the individ-
ually purified proteins were used in ELISA(30) to validate the specificity ofIgG antibodies
that were immunopurified against specific outer membrane proteins.
IgG Preparations
IgG subclasses 1, 2, and 3, but not 4 (31) were separated from the 4 U of pooled serum
by anion-exchange chromatography using QAE-Sephadex A-50 (Pharmacia Fine Chemi-
cals, Piscataway, NJ) gel equilibrated in a 0.048 M ethylene diamine, 0.073 M acetic acid
buffer, pH 7 .0 (32).Solid-phase Immunoabsorption
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Individual proteins, protein III or I, were coupled to Sepharose 4B (Pharmacia Fine
Chemicals) that was activated with cyanogen bromide and triethylamine, pH 7 .0 (33, 34).
This activation process favors the formation of cyanate esters that are predominantly
responsible for covalent coupling of ligand to the resin (33, 34). Purified proteins III and
I (I mg/ml) were dialyzed extensively against 0.1 M NaHCO3 buffer (pH 8.0) containing
0 .5 M NaCI and 0.05% Zwittergent (Behring Diagnostics, Somerville, NJ). The solutions
of proteins were added to the activated gels to obtain a 50% slurry and rotated end-over-
end overnight at VC. C. Afterallowing the gels to settle, the supernatant was removed and
assayed for protein (35). The remaining active groups were blocked by incubating the
gels with 0.1 M ethanolamine-HCI 9 (pH 8.0) overnight at VC. C. The gels were finally
equilibrated in 0.1 M Tris-HCI (pH 8.0). IgG preparations (0.5-1 .5 ml) were equilibrated
in PBS-Tween (0.05%) and applied to gel columns overnight (4°C) then washed with
PBS-Tween. Additional samples of IgG were applied to the columns and the same
procedure repeated for a total of three runs. After a final wash with PBS, columns were
brought to room temperature, the PBS exchanged for 2 M KI, and after 1 h the antibodies
were eluted from the columns with additional 2 M KI . The eluted preparations were
exchanged into 0.15 M NaCl, concentrated, and used promptly in the immunologic assays.
Control columns were also used, with mock-activated gels that were not reacted with
gonococcal proteins, but were blocked with ethanolamine. Immunodepletion of protein
III antibody from DGI-2 immune serum was also carried out after equilibration of the
serum with PBS-Tween and 10-4 mM pheny1methylsulfonyl fluoride. Immune serum was
passed over the protein III gel and control columns and used in the immunologic assays
after Tween-20 was removed by absorption with beads made of a copolymer of styrene-
divinyl benzene (Bio-Beads SM-Z; Bio-Rad Laboratories, Richmond, CA) (36).
Characterization of Purified Antibodies and Immunodepleted Serum
Western blots.
￿
The antibody specificities of normal IgG and antibodies purified from
normal IgG were examined by western blotting (27). In preliminary experiments the
antigenicity of the isolated proteins III and I used to prepare the immunoabsorbants was
also assessed using specific monoclonal antibodies: 2E6 for protein 111 (12) and 3G8 for
protein I (15). After SDS-PAGE (23, 24) ofantigen preparations, these were electroblotted
to nitrocellulose paper (Bio-Rad Laboratories) in a solution of 20% methanol (vol/vol)
containing 0.025 M Tris and 0.192 M glycine (pH 8.7). Transfer was carried out at
constant current (250 mA) for 2 h at room temperature and the papers were washed in
PBS with 0 .05% Tween-20 (27). Antibody containing solutions were diluted in 1% BSA-
PBS and 0.5 M NaCl . After the antibody was reacted with the nitrocellulose strips for 16
h at 4°C, specificity of binding was identified with alkaline phosphatase-conjugated goat
anti-mouse IgG or goat anti-human IgG (Sigma Chemical Co., St. Louis, MO) and blue
color was visualized after the addition of substrate containing nitroblue tetrazolium and
indoxyl phosphate in dimethylformamide (37).
Enzyme-linked immunosorbent assay (ELISA).
￿
Direct binding activity of antibodies in
serum, isolated IgG, and immunopurified or immunodepleted specimens were determined
by using a kinetic ELISA (30, 38) that employed purified antigens as coated targets on
microtiter wells. Quantitation of specific IgG antibodies was determined by comparing
rate of substrate conversion (change in absorbance) with change in absorbance in sepa-
rately performed IgG assays that used anti-IgG coated onto microtiter wells and known
concentrations of an IgG standard (Behring Diagnostics) (39). Total IgG concentrations
in specimens were also determined by using the identical assay performed for the IgG
standards. Polystyrene microtiter plates with round U-bottomed wells (Dynatech Labo-
ratories, Inc ., Alexandria, VA) were coated (250 Al/well) at 37°C for 3 h with a solution
of protein III (0.4 ug/ml) or protein I (2.5 ug/ml) in NaCO3 buffer (pH 9 .6) (30). LOS
was coated (60 ug/ml) in barbital acetate buffer (pH 4.6 (40). These concentrations were
predetermined to give optimal (highest) readings at the concentrations of specific antibody
where kinetic ELISA were to be performed. The standard curves used to establish changes
in optical densities vs. IgG concentration were developed in experiments that used wells173 8
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coated with affinity-purified goat anti-human IgG (Antibodies Inc., Davis, CA) at coating
concentration of 100 tcg/ml in NaCO3 buffer (39). Plates coated with anti-IgG or antigen
were shaken at 37°C for 3 h, after which they were stored overnight at 4°C and then
washed four times for 10 min each, by inversion in PBS-Tween (28). Experiments were
performed with (a) IgG antibodies immunopurified against proteins III and 1, (b) whole
DGI-2 serum, and (c) DGI-2 serum immunodepleted of protein III antibody. These
preparations were diluted in PBS-Tween and dispensed into the wells coated with test
antigens or anti-human IgG. Human IgG standards diluted in PBS-Tween were added
at concentrations ranging from 20 to 200 ng/ml to the "standard curve" wells coated with
antibody against human IgG. The remainder of the assay was performed as described
previously (28) using anti-human IgG conjugated with alkaline phosphatase (Sigma
Chemical Co.) and disodium lb-nitrophenyl phosphate as substrate. Incubations with
substrate were performed at 21 °C and absorbance readings (405 nm) were taken at 5-
min intervals for 30 min. A standard curve relating IgG concentration to rate of increase
of absorbance was constructed and specimen values were determined from the curve .
Controls used in these assays have been described previously (28).
Each ELISA experiment was performed in duplicate on three separate occasions and
the standard error of the mean of three experiments was used as a measure of variance.
Blocking assays. Bactericidal conditions and controls that were used as a basis against
which blockers were tested have been described previously (9). Test mixtures contained
0 .075 ml of bactericidal serum and blockers, 0.025 ml of gonococci, and 0.05 ml of active
complement. The following reagents were tested for their ability to block killing of the
test strain by homologous convalescent serum from the infected patient (DGI-1): (a) IgG
derived from normal human serum, and (b) normal IgG immunopurified against protein
III or I. Complement was obtained from the serum of a 27-yr-old woman with acquired
agammaglobulinemia (9).
IgG preparations or immunopurified IgG antibodies were diluted serially in 0 .05 ml
with 0.15 M saline and incubated for 15 min with the test dilution of the strain (0.025
ml) at 37 °C. Thereafter, 0.025 ml of a dilution of convalescent DGIA serum that had
produced an approximately ten-fold kill in the bactericidal assay, was added to the reaction
mixture together with 0.05 ml of complement. The reaction mixtures were incubated at
37'C with continuous shaking in a water bath (New Brunswick ScientificCo., Inc., Edison,
NJ). Viable colony counts were performed at 0 and 30 min by plating duplicate 0.025-ml
samples of each reaction mixture and the percent killing taken as the reduction of CFU .
Percent inhibition was calculated as the ratio of the differences in percent of killing
between DGI immune serum alone and the test specimen with added blocker: [(percent
kill, immune serum) - (percent kill, immune serum with blockers)]/[(percent kill, immune
serum) - (percent kill, negative control)]. The mean percent inhibition and range was
determined by performing each assay on two separate occasions.
Bactericidal experiments with the DGI-1 strain were also performed with whole DGI-
2 serum and serum that had been immunodepleted of protein III antibody. DGI-2 serum
that had been passed over mock columns was also tested as control. Concentrations of
serum up to 80% were included in these reaction mixtures and the 33 .33% concentration
of complement was contributed by each of the serum preparations. Protein III-depleted
serum and DGI-2 serum passed over control columns maintained 38% and 43%, respec-
tively, of the original 120 CH50 U/ml (41) .
Results
Immunochemical Characterization of Isolated Proteins III and I Usedfor Immuno-
purification. Isolated outer membranes and proteins III and I were examined
by SDS-PAGE and western blotting to assess purity and antigenicity of isolated
preparations. Fig. 1 demonstrates the gel patterns of isolated protein III and I
(lanes 3 and 7, respectively) compared with intact outer membranes (lane 2).
Recognition of isolated protein III by mAb 2E6 and protein I by mAb 3C8 (lanes
5 and 9, respectively) indicated that antigenicity of the proteins was maintainedRICE ET AL .
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FIGURE 1 .
￿
SDS-PAGE analysis of N . gonorrhoeae strain DGI-I outer membrane proteins;
immunochemical analysis by Western blots of (a) specific mAb against purified proteins III
and I and (b) immunopurified human IgG antibodies against proteins III and I . Lane 1,
standards; lane 2, SDS-PAGE of outer membranes of strain DGI-1 ; lane 3, SDS-PAGE of
purified protein III; lane 4, human IgG immunopurified against protein III and reacted with
protein III in Western blot ; lane 5, protein III-specific mAb 2E6 reacted with protein III in
Western blot; lane 6, protein I-specific mAb 3C8, reacted with protein III in Western blot ;
lane 7, SDS-PAGE of purified protein I; lane 8, human IgG immunopurified against protein
I and reacted with protein I in Western blot; lane 9, protein I-specific mAb 3C8, reacted with
protein I in Western blot; lane 10, protein I-specific mAb 2E6 reacted with protein I in
Western blot .
through the purification process, The heterologous mAb did not recognize
protein III material (lane 6) although minimal contamination (<I% [20]) of the
protein I preparation (not visualized with a sensitive silver stain [26], lane 7) was
identified by mAb 2E6 (lane 10). These isolated protein preparations served as
effective immunoabsorbants when coupled to gels, as evidenced by successful
rebinding to respective antigens of human IgG that had been immunopurified
against protein III (lane 4) and IgG immunopurified against protein I (lane 8) .
Specificity ofImmunopurified IgG.
￿
Human IgGimmunopurified against protein
III and I antigens was assessed for specificity in western blotting experiments
that employed the whole outer membrane as target antigen (Fig . 2) . Although
whole IgG was seen to bind to a number of proteins in addition to major
gonococcal proteins III and I (also protein II [42], lane 3), immunopurified
antibody against protein III bound only to the protein III antigen (lane 4) . In
separate experiments (not shown) this antibody also binds to reduction-modified
protein III (11, 12) at a slightly higherM r. Antibody purified against protein I
was shown to bind principally at the location of protein I (36,200 M,, lane 5),
however binding was also demonstrated at several additional locations; these
locations corresponded in part to stained bands seen on the gel of protein I (Fig .
1, lane 7) . This may also have included faint bindingto a small amount ofprotein
III present in this preparation . Antibody binding to LOS was not seen in western
blots that used the whole IgG preparation, however, experimental conditions
optimal for binding to outer membrane proteins were not favorable for IgG1740 ANTIBODY BLOCKS NEISSERIA GONORRHOEAE KILLING
FIGURE 2 .
￿
SDS-PAGE analysis ofN . gonorrhoeae strain DGI-1 outermembranesand Western
blots of whole IgG and purified IgG antibodies reacted with outer membrane antigens . Lane
1, standards; lane 2, SDS-PAGE of outer membranes of strain DGI-1 ; lane 3, human IgG
reacted with outer membranes in Western blot ; lane 4, human IgG immunopurified against
protein III andreacted with outermembranes in Western blots ; lane 5, human IgGimmuno-
purified against protein I and reacted with outer membranes in Western blots.
Preparation
TABLE I
SpeckAntibody Activity* in Serum-derived Fractions
Target antigens$
Protein III
￿
Protein I
￿
LOS
IgG preparation
￿
2.08 ± 0.06
￿
3.01 ± 1 .0
￿
0.70 ± 0.04
Protein III eluent
￿
98 ± 7 .2
￿
<0.06¢
￿
<0.06§
Protein I eluent
￿
0.07 ± 0.01
￿
75 .1 ± 10 .1
￿
<0 .06§
* (micrograms of measured antibody [IgG]) X 10-"/(micrograms IgG)
$ Antigens used in ELISAwere prepared from DGI-1 .
§ ODs were less than negative controls .
binding to LOS antigens . This was evident when we measured IgG antibodies
against LOS in the whole IgG preparation using ELISA (Table I) .
Specific antibody activity against the two isolated proteins, in addition to LOS,
was determined by ELISA (Table I) . The specific activity of protein III antibody
was enhanced 47-fold in the protein III eluent compared with the whole IgG
preparation . The absence of measurable antibody against protein I in the protein
III eluent confirmed results of western blotting . The specific activity of protein
I antibody was enhanced 25-fold in the protein I eluent . 3.4% of protein III-
specific activity remained in this preparation, possibly the result ofa smallamount
of protein III that was present in the protein I preparation used for immunopur-
ification . LOS antibody was not detected in either preparation, indicating >91
purity of these preparations from LOS antibody .
BlockingAssays.
￿
Whole IgG and protein III and I antibodies immunopurified
from IgG were tested for blocking activity . As previously reported (7, 9, 14),
IgG blocks killing by immune human serum of gonococci that otherwise resist
killing by NHS (Fig . 3) . Purified protein III antibody effectively blocked killing100
50
/
Pii, antibody
i
￿
P, antibody
.01
￿
.1
RICE ET AL.
￿
1741
[19G]. blocking reparation
g
￿
, killing serum
FIGURE 3.
￿
Inhibition of convalescent immune serum killingof N. gonorrhoeae strain DGI-1
by IgG isolated from NHS and by antibodies immunopurified against proteins III and I.
Percent inhibition is expressed as a function of the ratioof IgG concentration in the blocking
preparation divided by the IgG concentration in the killing serum. ([I) Protein III (PIII)
antibody heated to 65°C. (a) IgG heated to 65°C. n = two experiments ± range.
in a dose-related fashion. Purified protein I antibody displayed no blocking
activity, and at the highest concentration used in these studies showed modest
bactericidal ability in the absence of the killer immune serum (experiments not
shown) . Eluents recovered from control columns showed no blocking or bacte-
ricidal activity. Heating of IgG and antibody preparations to 65°C to destroy
antibody function eliminated blocking activity (Fig. 3). Heating to 570C for 30
min had no effect.
Protein III antibody requirements for blocking in whole IgG preparation was
compared with that in the purified PIII antibody preparation. This comparison
revealed that purified protein III antibody maintained blocking activity equiva-
lent to protein III antibody in whole IgG (Fig. 4). These results suggest that
blocking activity in whole IgG may be caused predominantly by the action of
antibodies directed against PI11.
A second immune DGI serum (DGI-2) that had been chosen for study because
it lacked killing activity at high concentration against the DGI-1 test strain was
depleted of protein III antibody and tested in the bactericidal assay. Serum
passed over the protein III immunoabsorbant column was depleted of 96% of
protein III antibody while protein I and LOS antibody concentrations were
maintained (Table II). Bactericidal assays were performed with protein III
antibody depleted sera and its whole serum counterpart (Fig. 5). Whole serum
demonstrated a bactericidal prozone (Neisser-Wechsberg phenomenon [43])
with emergence ofkilling as the serum was diluted. Selective removal ofprotein
III antibody eliminated the prozone and unmasked killing activity at the highest
concentration ofabsorbed serum used in the assay (Fig. 5). Whole serum passed
over control columns maintained between 76 and 92% of blocking activity1742
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FIGURE 4.
￿
Inhibition of convalescent immune serum killing of N. gonorrhoeae strain DGI-1
by whole IgG and purified protein III (PIII) antibodies. Percent inhibition is expressed as a
function ofthe amount of PIII antibody, measured by kinetic ELISA, in blocking preparations
that were employed in the assays. n = two experiments ± range.
TABLE 11
Antibody Concentrations in DGI-2 Serum and DGI-2 Serum Immunodepleted
ofProtein III Antibody
Target antigen*
Protein III
￿
Protein I
￿
LOS
wg/ml
DGI-2 serum
￿
1 .78 ± 0.15
￿
12.21 ± 3 .2
￿
75 .62 ± 7.2
DGI-2 (immunodepleted of
￿
0.073 ± 0.01
￿
10.6 ± 5.4
￿
71 .3 ± 5.2
protein III antibody)
* Antigens used in ELISA were prepared from the test strain (DGI-1).
FIGURE 5.
￿
Killing action of DGI-2 serum and DGI-2 serum depleted of 96% of protein III
(PIII) antibody, against N. gonorrhoeae strain DGI-1 . Percent killing is expressed as a function
ofpercent of serum in the bactericidal reaction mixture. n = two experiments ± range.RICE ET AL.
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present in unabsorbed serum, when tested ateach ofthe concentrations indicated
in Fig. 5 for whole serum.
Discussion
We have shown in these studies thatblocking IgG with specificity foracommon
gonococcal surface protein, protein III, contributes a major portion of blocking
activity in normal and immune serums. Blocking IgG competes for binding sites
on gonococcal surfaces with bactericidal antibody, resulting in effective preven-
tion of complement-dependent killing (7). This contributes to an explanation of
why certain strains of N. gonorrhoeae are resistant to killing by NHS. Immune
and normal bactericidal antibodies against both serum-resistant and serum-
sensitive strains of N. gonorrhoeae, respectively, are directed mainly against LOS
(17, 44). Normal and convalescent serum may contain antibodies that recognize
protein I; these antibodies may also be bactericidal (18) particularly when they
are tested in the absence ofblocking antibodies (unpublished observations). The
intimate relationship ofproteins III and I (13, 45, 46), which in turn appears to
be tightly bound to LOS (47), indicates that binding sites for bactericidal and
blocking antibodies are in close proximity. Based on estimates of the density
distribution of LOS and protein I molecules on the surface of gonococci and
their relationship to protein III, antibody binding to protein III might be
expected to obscure certain binding sites present on either LOS or protein I.
Extensive serologic testing for the presence of protein III antibodies in NHS
have not been performed, however many sera that have been tested contain IgG
antibodies against this antigenically conserved surface protein (48, unpublished
observations). In addition, the observation that the development of bactericidal
activity in patients convalescing from DGI is often nonexistent or meager (3),
despite high-titered antibody rises measured by indirect immunofluorescence
(49) or ELISA (unpublished data), suggests that blocking antibodies may result
from specific antigenic challenge. We have shown in these studies that selective
protein III antibody depletion from DGI convalescent serum with unexpressed
bactericidal activity restores killing activity to the serum.
Evidence ofthe specificity of binding ofblocking antibody is also provided by
our previous studies that have demonstrated equivalent blocking activity by
F(ab')2 fragments prepared from normal IgG (7, 9). We also found previously
that low concentrations of F(ab')2 blocking antibody effectively inhibited the
binding of the protein III-specific mAb 2E6 to the strain used in the current
studies (7). In a study that used a different serum-resistant strain, FA171, NHS
was also shown to inhibit binding of mAb 2E6 (50). In those studies, most ofthe
inhibition ofmAb 2E6 binding was removed by absorption of NHS with purified
protein I, which suggests that steric hindrance to nearby antibody combining
sites also played a critical role in those competition binding studies. Using a third
serum-resistant strain, R11, joiner et al. (10) also demonstrated that mAb 2E6
could inhibit binding ofa protein I mAb to the surface of this strain.
Serum bactericidal antibodies are associated with protection of the human host
against invasive infection with N. meningitidis (51, 52) andHaemophilus influenzae
(53). Currently, the role of complement-dependent serum bacterididal activity
in the host defense against the three major categories of gonococcal infection-1744
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uncomplicated, locally invasive (i.e., PID), and bacteremic infection is incom-
pletely defined. Serum bactericidal activity directed against gonococci that cause
uncomplicated local infection appears not to protect against this disease (54). Its
absence in women with PID infected with gonococci, otherwise sensitive to NHS,
may indicate susceptibility to locally invasive strains in these women (54) . In
addition, we have reported earlier that some DGI strains are killed by NHS, yet
patients infected with these strains lack bactericidal activity at the time they are
infected (3). We have also observed variations in resistance or sensitivity to the
bactericidal action of NHS of strains that cause different types of invasive disease
and this may prove to be an important factor that enables strains to produce
varying patterns of inflammation resulting in the distinct manifestations of
gonococcal infection (2, 3).
The complex interaction between the surface antigens of gonococci and the
host may reflect both the inflammatory potential and the sensitivity to serum of
N. gonorrhoeae. The contribution of blocking antibodies to the varying manifes-
tations of gonococcal infection has not been clarified, but these antibodies have
also been described with infections caused by other bacteria. In the first written
account of serum blocking activity, Neisser and Wechsberg (43) described a wide
range of gram-negative organisms wherethe killingaction of normal fresh animal
sera was blocked by immune sera taken from animals that had been immunized
with whole bacteria. In 1943, Thomas and Dingle (55) described the loss of
natural bactericidal activity in normal rabbits after passive intravenous immuni-
zation with antimeningococcal horse serum. This resulted in longer periods of
bacteremia after the intravenous injection of meningococci. Sera taken from
patients early in the course of meningococcal disease may have lytic activity
against the infecting strain that is unmasked only when the sera have been freed
of IgA (56) . Convalescent sera from patients infected with the meningogoccus
may show diminished bactericidal activity against the infecting strain and may
also inhibit killing of meningococci by sera from normal humans (57). Similar
inhibition has also been demonstrated in the sera of patients chronically infected
with common enteric Gram-negative bacilli (58-60) and in the IgA fraction of
sera taken from patients with chronic brucellosis (61).
The mechanisms of action of the blocking antibody for N. gonorrhoeae has not
previously been known. In addition to displacing bactericidal antibody from
gonococcal surfaces, it has been speculated that, like blocking antibody for N.
meningitidis and Brucella abortus, which are of the IgA isotype and therefore
unable to activate complement effectively, blocking IgG for N. gonorrhoeae and
for otherGram-negative organisms (58-60) may be predominantly those isotypes
of IgG that activate complement poorly . Blocking IgG, used in our studies,
contained exclusively complement-fixing subclasses (IgG4 was excluded), and in
separate studies it has been shown that organisms opsonized with blocking IgG
increased consumption and deposition of the third (C3) and ninth (C9) compo-
nents of complement (7). While ^-25% of C3 deposited onto N. gonorrhoeae in
the presence of blocking antibody is covalently bound to the antibody molecule,
C3 deposition is also redirected to new sites on the gonococcal surface that do
not result in serum killing (7).
Although our studies have shown that human sera contain protein III-specificRICE ET AL.
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antibodies that are predominantly responsible for blocking activity, nonetheless
it is possible that the nature of the antibody itself or the location of the epitope
on the organism recognized by the antibody, in addition to the antigenic
specificity, may dictate whether killing or blocking will supervene. Such an
assumption is based on several observations: (a) different ratios of protein III-
blocking antibody to bactericidal antibody are required in individual sera to
achieve constant blocking (unpublished observations); (b) different mAb, all
directed at a single protein I, can vary in bactericidal activity for N. gonorrhoeae,
and indeed, nonkilling mAb against protein I can effectively block killing anti-
bodies that recognize different epitopes on this protein (13); (c) IgA blocking
antibody, which is specific for LOS, can sometimes block IgG anti-LOS killing
of serum-resistant gonococci (62); and (d) protein III mAb 2E6 is bactericidal
for some strains of N. gonorrhoeae at high concentrations (K. A. Joiner and J.
Swanson, unpublished observations; P. A. Rice, unpublished observations). In
humans, however, protein III antibody competes for binding with bactericidal
antibody, leads to deposition of nonbactericidal C5b-9, and can prevent killing
ofgonococci by bactericidal antibody.
Summary
Neisseria gonorrhoeae that resist complement-dependent killing by normal hu-
man serum (NHS) are sometimes killed by immune convalescent serum from
patients recovering from disseminated gonococcal infection (DGI). In these
studies, killing by immune serum was prevented or blocked by IgG isolated from
NHS. Purified human IgG antibodies directed against gonococcal protein III,
an antigenically conserved outer membrane protein, contained most of the
blocking activity in IgG. Antibodies specific for gonococcal porin (protein 1), the
major outer membrane protein, displayed no blocking function.
In separate experiments, immune convalescent DGI serum which did not
exhibit bactericidal activity was restored to killing by selective depletion of
protein III antibodies by immunoabsorption . These studies indicate that protein
IIIantibodies in normal and immune human serum playarole in serum resistance
of N. gonorrhoeae.
The authors thank Sunita Gulati, M.S., for expert technical assistance and Luzvisminda
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